Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
12
users have liked this narrative
8
users have commented on this narrative
49
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Venus Pipes and Tubes
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Capacity And Exports Will Fuel Robust Infrastructure Demand
Key Takeaways Capacity expansion into value-added products and automation are set to boost margins, operational efficiency, and position Venus for long-term, sustainable profit growth. Growing export footprint and leadership in organized, high-grade domestic segments reduce risk, enable market share gains, and ensure robust sales momentum.
View narrative
₹1.92k
FV
31.2% undervalued
intrinsic discount
24.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
3 days ago
author updated this narrative
Sprout Social
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
AI Expansion And Cloud SaaS Will Unlock Global Markets
Key Takeaways AI-powered innovation and acquisitions are driving adoption of premium offerings, deeper enterprise integration, and more stable, diversified revenue streams. Global expansion and advanced compliance solutions position Sprout Social to capture regulated industries and mitigate region-specific risks.
View narrative
US$22.82
FV
38.2% undervalued
intrinsic discount
12.25%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
National Atomic Company Kazatomprom JSC
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Global Nuclear Expansion Will Unlock Enduring Uranium Value
Key Takeaways Strong global uranium demand and supply deficits strengthen Kazatomprom's long-term pricing power, revenue growth, and earnings stability. Ongoing investment and downstream expansion support low-cost leadership and create new, higher-margin revenue streams.
View narrative
US$52.73
FV
14.7% undervalued
intrinsic discount
14.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
27
users have followed this narrative
3 days ago
author updated this narrative
Apellis Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
FDA Label Expansion And SYFOVRE Will Unlock Future Value
Key Takeaways Expansion into rare kidney diseases and strong leadership in eye disease treatments set the stage for revenue growth and increased market reach. Enhanced balance sheet and operational efficiency enable greater investment in R&D and commercialization, supporting profitability and long-term earnings potential.
View narrative
US$37.74
FV
26.5% undervalued
intrinsic discount
18.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
3 days ago
author updated this narrative
Penguin Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
AI And Digital Transformation Will Drive Global Data Center Success
Key Takeaways Strong growth is supported by increasing AI-driven demand, expanding services, and key partnerships that enhance product innovation and earnings stability. Customizable, energy-efficient solutions and a broadening sales pipeline position the company to gain additional market share and improve profitability.
View narrative
US$27.13
FV
12.4% undervalued
intrinsic discount
10.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
3 days ago
author updated this narrative
Tristel
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
US Expansion And Direct Sales Will Open New Opportunities
Key Takeaways Geographic expansion, especially into the U.S., is expected to drive significant revenue growth in medical device decontamination. A shift to direct sales and strong OEM partnerships could enhance profitability by capturing more value and increasing product adoption rates.
View narrative
UK£4.48
FV
19.7% undervalued
intrinsic discount
11.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
3 days ago
author updated this narrative
AXT
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
High-Speed Data Connectivity And AI Infrastructure Will Expand Global Reach
Key Takeaways Leadership in high-quality substrate materials and easing export headwinds position AXT for strong revenue growth and higher margins in the AI and data connectivity markets. Diversification into new markets and improved manufacturing processes are set to reduce risk, optimize costs, and support sustained long-term earnings growth.
View narrative
US$3.82
FV
46.3% undervalued
intrinsic discount
11.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
3 days ago
author updated this narrative
Delcath Systems
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Expanded Clinical Trials And Program Integration Will Define Oncology's Future
Key Takeaways Growing demand for liver-focused cancer treatments and broader clinical trials are expanding Delcath's addressable markets and supporting long-term revenue growth. Increased market access, hospital adoption, and European expansion are driving sustained volume growth and profitability despite some downward pricing pressure.
View narrative
US$24.33
FV
57.4% undervalued
intrinsic discount
37.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
3 days ago
author updated this narrative
ARS Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Worldwide Allergy Trends Will Expand Needle-Free Treatment Access
Key Takeaways Accelerating demand and expanded access for neffy, especially in pediatric and school settings, is driving significant revenue and earnings growth opportunities. Global expansion, new clinical indications, and strong market penetration strategies are broadening revenue streams and creating multiple long-term growth drivers.
View narrative
US$31.00
FV
53.1% undervalued
intrinsic discount
54.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies